524 related articles for article (PubMed ID: 32278354)
1. Transgenic mice expressing tunable levels of DUX4 develop characteristic facioscapulohumeral muscular dystrophy-like pathophysiology ranging in severity.
Jones TI; Chew GL; Barraza-Flores P; Schreier S; Ramirez M; Wuebbles RD; Burkin DJ; Bradley RK; Jones PL
Skelet Muscle; 2020 Apr; 10(1):8. PubMed ID: 32278354
[TBL] [Abstract][Full Text] [Related]
2. A cre-inducible DUX4 transgenic mouse model for investigating facioscapulohumeral muscular dystrophy.
Jones T; Jones PL
PLoS One; 2018; 13(2):e0192657. PubMed ID: 29415061
[TBL] [Abstract][Full Text] [Related]
3. Facioscapulohumeral muscular dystrophy family studies of DUX4 expression: evidence for disease modifiers and a quantitative model of pathogenesis.
Jones TI; Chen JC; Rahimov F; Homma S; Arashiro P; Beermann ML; King OD; Miller JB; Kunkel LM; Emerson CP; Wagner KR; Jones PL
Hum Mol Genet; 2012 Oct; 21(20):4419-30. PubMed ID: 22798623
[TBL] [Abstract][Full Text] [Related]
4. Improving Molecular and Histopathology in Diaphragm Muscle of the Double Transgenic ACTA1-MCM/FLExDUX4 Mouse Model of FSHD with Systemic Antisense Therapy.
Lu-Nguyen N; Malerba A; Antoni Pineda M; Dickson G; Popplewell L
Hum Gene Ther; 2022 Sep; 33(17-18):923-935. PubMed ID: 35078334
[TBL] [Abstract][Full Text] [Related]
5. Muscle eosinophilia is a hallmark of chronic disease in facioscapulohumeral muscular dystrophy.
Nunes AM; Ramirez MM; Garcia-Collazo E; Jones TI; Jones PL
Hum Mol Genet; 2024 May; 33(10):872-883. PubMed ID: 38340007
[TBL] [Abstract][Full Text] [Related]
6. Transgenic Drosophila for Investigating DUX4 and FRG1, Two Genes Associated with Facioscapulohumeral Muscular Dystrophy (FSHD).
Jones TI; Parilla M; Jones PL
PLoS One; 2016; 11(3):e0150938. PubMed ID: 26942723
[TBL] [Abstract][Full Text] [Related]
7. Expression of DUX4 in zebrafish development recapitulates facioscapulohumeral muscular dystrophy.
Mitsuhashi H; Mitsuhashi S; Lynn-Jones T; Kawahara G; Kunkel LM
Hum Mol Genet; 2013 Feb; 22(3):568-77. PubMed ID: 23108159
[TBL] [Abstract][Full Text] [Related]
8. Transgenic zebrafish model of DUX4 misexpression reveals a developmental role in FSHD pathogenesis.
Pakula A; Lek A; Widrick J; Mitsuhashi H; Bugda Gwilt KM; Gupta VA; Rahimov F; Criscione J; Zhang Y; Gibbs D; Murphy Q; Manglik A; Mead L; Kunkel L
Hum Mol Genet; 2019 Jan; 28(2):320-331. PubMed ID: 30307508
[TBL] [Abstract][Full Text] [Related]
9. Muscle pathology from stochastic low level DUX4 expression in an FSHD mouse model.
Bosnakovski D; Chan SSK; Recht OO; Hartweck LM; Gustafson CJ; Athman LL; Lowe DA; Kyba M
Nat Commun; 2017 Sep; 8(1):550. PubMed ID: 28916757
[TBL] [Abstract][Full Text] [Related]
10. Identification of candidate miRNA biomarkers for facioscapulohumeral muscular dystrophy using DUX4-based mouse models.
Nunes AM; Ramirez M; Jones TI; Jones PL
Dis Model Mech; 2021 Aug; 14(8):. PubMed ID: 34338285
[TBL] [Abstract][Full Text] [Related]
11. p53-independent DUX4 pathology in cell and animal models of facioscapulohumeral muscular dystrophy.
Bosnakovski D; Gearhart MD; Toso EA; Recht OO; Cucak A; Jain AK; Barton MC; Kyba M
Dis Model Mech; 2017 Oct; 10(10):1211-1216. PubMed ID: 28754837
[TBL] [Abstract][Full Text] [Related]
12. Systemic antisense therapeutics inhibiting DUX4 expression ameliorates FSHD-like pathology in an FSHD mouse model.
Lu-Nguyen N; Malerba A; Herath S; Dickson G; Popplewell L
Hum Mol Genet; 2021 Jul; 30(15):1398-1412. PubMed ID: 33987655
[TBL] [Abstract][Full Text] [Related]
13. Influence of
Duranti E; Villa C
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298453
[TBL] [Abstract][Full Text] [Related]
14. Identification of Epigenetic Regulators of DUX4-fl for Targeted Therapy of Facioscapulohumeral Muscular Dystrophy.
Himeda CL; Jones TI; Virbasius CM; Zhu LJ; Green MR; Jones PL
Mol Ther; 2018 Jul; 26(7):1797-1807. PubMed ID: 29759937
[TBL] [Abstract][Full Text] [Related]
15. DUX4 Transcript Knockdown with Antisense 2'-O-Methoxyethyl Gapmers for the Treatment of Facioscapulohumeral Muscular Dystrophy.
Lim KRQ; Bittel A; Maruyama R; Echigoya Y; Nguyen Q; Huang Y; Dzierlega K; Zhang A; Chen YW; Yokota T
Mol Ther; 2021 Feb; 29(2):848-858. PubMed ID: 33068777
[TBL] [Abstract][Full Text] [Related]
16. DUX4 Signalling in the Pathogenesis of Facioscapulohumeral Muscular Dystrophy.
Lim KRQ; Nguyen Q; Yokota T
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 31979100
[TBL] [Abstract][Full Text] [Related]
17. Direct interplay between two candidate genes in FSHD muscular dystrophy.
Ferri G; Huichalaf CH; Caccia R; Gabellini D
Hum Mol Genet; 2015 Mar; 24(5):1256-66. PubMed ID: 25326393
[TBL] [Abstract][Full Text] [Related]
18. DUX4-induced gene expression is the major molecular signature in FSHD skeletal muscle.
Yao Z; Snider L; Balog J; Lemmers RJ; Van Der Maarel SM; Tawil R; Tapscott SJ
Hum Mol Genet; 2014 Oct; 23(20):5342-52. PubMed ID: 24861551
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of the double homeodomain protein DUX4c interferes with myofibrillogenesis and induces clustering of myonuclei.
Vanderplanck C; Tassin A; Ansseau E; Charron S; Wauters A; Lancelot C; Vancutsem K; Laoudj-Chenivesse D; Belayew A; Coppée F
Skelet Muscle; 2018 Jan; 8(1):2. PubMed ID: 29329560
[TBL] [Abstract][Full Text] [Related]
20. Transcriptional and cytopathological hallmarks of FSHD in chronic DUX4-expressing mice.
Bosnakovski D; Shams AS; Yuan C; da Silva MT; Ener ET; Baumann CW; Lindsay AJ; Verma M; Asakura A; Lowe DA; Kyba M
J Clin Invest; 2020 May; 130(5):2465-2477. PubMed ID: 32250341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
